media
....In a midstage study of 204 patients, rucaparib shrunk tumors in 32 of 39
patients with BRCA mutations. Four women in that group had their tumors
disappear, known as a complete response. The study data was released
Saturday at the American Society of Clinical Oncology’s meeting in
Chicago.....
An ovarian cancer blog which includes quality resource materials: education, research, social networking, genetics and (some) healthcare politics.
“Not everything that can be counted counts and not everything that counts can be counted.”
Albert Einstein
No comments:
Post a Comment
Your comments?
Note: Only a member of this blog may post a comment.